Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
211
datasets available to search
ShareScore release 0.9.0
Dataset results
211 results for “autoantibody”
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201
ClinicalTrials.gov study NCT04422912. IPD Sharing: NO. Countries: 1. Publications: 0.
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
ClinicalTrials.gov study NCT01275287. IPD Sharing: NO. Countries: 1. Publications: 1.
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
ClinicalTrials.gov study NCT05182515. IPD Sharing: YES. Countries: 1. Publications: 16.
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
ClinicalTrials.gov study NCT06334692. IPD Sharing: NO. Countries: 1. Publications: 9.
Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
ClinicalTrials.gov study NCT04659200. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
ClinicalTrials.gov study NCT05193591. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
Role of Anti-TREK-1 Autoantibodies in SCVF
ClinicalTrials.gov study NCT06943365. IPD Sharing: NO. Countries: 1. Publications: 3.
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
ClinicalTrials.gov study NCT05414890. IPD Sharing: NO. Countries: 1. Publications: 2.
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
ClinicalTrials.gov study NCT06762002. IPD Sharing: NO. Countries: 1. Publications: 3.
Descartes-08 in Autoantibody Myositis
ClinicalTrials.gov study NCT07391605. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Autoimmune Diseases and Serum Autoantibodies in NCWS and IBS Patients
ClinicalTrials.gov study NCT04077840. IPD Sharing: NO. Countries: 1. Publications: 10.
Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein
ClinicalTrials.gov study NCT03345537. IPD Sharing: NO. Countries: 1. Publications: 15.
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
ClinicalTrials.gov study NCT04192214. IPD Sharing: NO. Countries: 1. Publications: 3.
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
ClinicalTrials.gov study NCT03864185. IPD Sharing: NO. Countries: 1. Publications: 1.
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
ClinicalTrials.gov study NCT07316465. IPD Sharing: NO. Countries: 1. Publications: 3.
Autoantibodies against the prion protein in individuals with PRNP mutations
Open the record for dataset details and reuse information.
Data from: Autoantibody prevalence in active tuberculosis: reactive or pathognomonic?
Open the record for dataset details and reuse information.
Epitope-specific anti-C1Q autoantibodies in systemic Lupus Erythematosus
<p><strong>Objective</strong></p> <p>In patients with <span>systemic lupus erythematosus</span> (SLE) complement C1q is frequently targeted by autoantibodies (anti-C1q), that correlate best with active renal disease. Anti-C1q bind to largely unknown epitopes on the collagen-like region (CLR) of this highly functional molecule. Here we aimed at exploring the role of epitope-specific anti-C1q in SLE patients.</p> <p><strong>Methods</strong></p> <p class="MsoNoSpacing">First, 22 sera of SLE patients, healthy controls and anti-C1q positive patients without SLE were screened for anti-C1q epitopes by a PEPperMAP® microarray, expressing CLR of C1q derived peptides with one amino acid (AA) shift in different lengths and conformations. Afterwards, samples of 378 SLE patients and 100 healthy blood donors were analyzed for antibodies against the identified epitopes by peptide-based ELISA. Relationships between peptide-specific autoantibodies and SLE disease manifestations were explored by logistic regression models.</p> <p><strong>Results</strong></p> <p>The epitope mapping showed increased IgG binding to three peptides of the C1q A- and three of the C1q B-chain. In subsequent peptide-based ELISAs, SLE sera showed significantly higher binding to two N-terminally located C1q A-chain peptides than controls (p < 0.0001), but not to the other peptides. While anti-C1q were associated with a broad spectrum of disease manifestations, some of the peptide-antibodies were associated with selected disease manifestations, and antibodies against the N-terminal C1q A-chain showed a stronger discrimination between SLE and controls than conventional anti-C1q.</p> <p><strong>Conclusion</strong></p> <p>In this large explorative study anti-C1q correlate with SLE overall disease activity. In contrast, peptide-antibodies are associated with specific aspects of the disease suggesting epitope-specific effects of anti-C1q in patients with SLE.</p>
Raw results of nanoLC-Q-TOF-MS /MS for four immunoblotting spots with elevated autoantibody levels in early ESCC.
<p>NanoLC-Q-TOF-MS/MS was used to identified the candidate autoantibodies which were detected from the serum of ESCC patients but not from healthy controls. Mascot searching engine were used to make a confirmation of the information provided by MS spectrum. In the database are the original results of the immunoblotting spots that we screened.</p>
Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT05179018. IPD Sharing: Not stated. Countries: 0. Publications: 12.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.